Joseph C Gathe - JoVE Visualize

Showing results (11-20 of 24) with videos related to

Pageof 3

Sort By:

Antimicrobial Agents and Chemotherapy|September 24, 2008

Safety and efficacy of enfuvirtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification studyEdwin DeJesus, Michael S Gottlieb, Joseph C Gathe, et al.

AIDS (London, England)|July 9, 2004

SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patientsJoseph C Gathe, Prudence Ive, Robin Wood, et al.

The Journal of Infectious Diseases|March 5, 2005

Administration of protein-conjugate pneumococcal vaccine to patients who have invasive disease after splenectomy despite their having received 23-valent pneumococcal polysaccharide vaccineDaniel M Musher, Heather Ceasar, Erna M Kojic, et al.

Clinical Therapeutics|July 25, 2006

Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on studyJoseph C Gathe, Robin Wood, Ian Sanne, et al.

AIDS Research and Human Retroviruses|July 1, 2009

Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263)Lisa Ross, Richard Elion, Randall Lanier, et al.

BMC Infectious Diseases|June 11, 2003

Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patientsJeffrey P Nadler, Joseph C Gathe, Richard B Pollard, et al.

AIDS Research and Human Retroviruses|February 1, 2007

Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patientsJoseph C Gathe, Gerald Pierone, Peter Piliero, et al.

HIV Clinical Trials|December 7, 2017

Pharmacokinetic analysis of nevirapine extended release 400 mg once daily vs nevirapine immediate release 200 mg twice daily formulation in treatment-naïve patients with HIV-1 infectionChan-Loi Yong, Joseph C Gathe, Gabriele Knecht, et al.

Journal of Acquired Immune Deficiency Syndromes (1999)|September 5, 2006

A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimenMargaret A Johnson, Joseph C Gathe, Daniel Podzamczer, et al.

AIDS Research and Human Retroviruses|March 19, 2009

Predictors of loss of virologic response in subjects who simplified to lopinavir/ritonavir monotherapy from lopinavir/ritonavir plus zidovudine/lamivudineRafael E Campo, Barbara A Da Silva, Laurent Cotte, et al.

Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:

Pageof 3

Antimicrobial Agents and Chemotherapy|September 24, 2008

Safety and efficacy of enfuvirtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification studyEdwin DeJesus, Michael S Gottlieb, Joseph C Gathe, et al.

AIDS (London, England)|July 9, 2004

SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patientsJoseph C Gathe, Prudence Ive, Robin Wood, et al.

The Journal of Infectious Diseases|March 5, 2005

Administration of protein-conjugate pneumococcal vaccine to patients who have invasive disease after splenectomy despite their having received 23-valent pneumococcal polysaccharide vaccineDaniel M Musher, Heather Ceasar, Erna M Kojic, et al.

Clinical Therapeutics|July 25, 2006

Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on studyJoseph C Gathe, Robin Wood, Ian Sanne, et al.

AIDS Research and Human Retroviruses|July 1, 2009

Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263)Lisa Ross, Richard Elion, Randall Lanier, et al.

BMC Infectious Diseases|June 11, 2003

Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patientsJeffrey P Nadler, Joseph C Gathe, Richard B Pollard, et al.

AIDS Research and Human Retroviruses|February 1, 2007

Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patientsJoseph C Gathe, Gerald Pierone, Peter Piliero, et al.

HIV Clinical Trials|December 7, 2017

Pharmacokinetic analysis of nevirapine extended release 400 mg once daily vs nevirapine immediate release 200 mg twice daily formulation in treatment-naïve patients with HIV-1 infectionChan-Loi Yong, Joseph C Gathe, Gabriele Knecht, et al.

Journal of Acquired Immune Deficiency Syndromes (1999)|September 5, 2006

A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimenMargaret A Johnson, Joseph C Gathe, Daniel Podzamczer, et al.

AIDS Research and Human Retroviruses|March 19, 2009

Predictors of loss of virologic response in subjects who simplified to lopinavir/ritonavir monotherapy from lopinavir/ritonavir plus zidovudine/lamivudineRafael E Campo, Barbara A Da Silva, Laurent Cotte, et al.

Pageof 3